ArticleFrontiers in oncology2021
Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study.
Registry-linked trialAbstract readCase Reports
In one paragraph
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06946602 (Bu/Cy/Flu/ATG Versus Bu/Cy/ATG Conditioning Regimen in Elderly AML Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation), which is not on this map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bu/Cy/Flu/ATG Versus Bu/Cy/ATG Conditioning Regimen in Elderly AML Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation: a Prospective, Randomized, Controlled Study
Who cites it
18 citing papers in PubMed.
- [The causes of death in elderly patients undergoing haploidentical stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes.Bone marrow transplantation · 2026Review
- Advancements in diagnosis and treatments of acute leukemia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- [Efficacy and safety of basiliximab in gastrointestinal chronic graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- A novel and safe protocol for patients with severe comorbidity who undergo haploidentical hematopoietic stem cell transplantation: A single-center prospective study.Journal of translational internal medicine · 2025Article
- Optimization of T-cell-replete haploidentical hematopoietic stem cell transplantation: the Chinese experience.Haematologica · 2025Review
- [Progress in hematopoietic stem cell transplantation for acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- A novel reduced toxicity conditioning regimen for older myelodysplastic neoplasms patients undergoing haploidentical stem cell transplantation: a prospective cohort study.American journal of cancer research · 2025Article
- Conditioning Regimen Options.Advances in experimental medicine and biology · 2025Review
- [Clinical analysis of oral mucositis after secondary allogeneic hematopoietic stem cell transplantation in patients with hematological diseases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group.Bone marrow transplantation · 2024Article
- VEXAS Syndrome: A Comprehensive Review of Current Therapeutic Strategies and Emerging Treatments.Journal of clinical medicine · 2024Review
- Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients.Annals of hematology · 2024Article
- [The present and future of haploidentical hematopoietic stem cell transplantation in China].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Comparison of haploidentical hematopoietic stem cell transplantation with chemotherapy in older adults with acute myeloid leukemia.Bone marrow transplantation · 2023Article
- The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.Journal of hematology & oncology · 2021Article
- Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Yu-Qian SunNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Ting-Ting HanNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yu WangNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Chen-Hua YanNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Feng-Rong WangNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Zhi-Dong WangNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Jun KongNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yu-Hong ChenNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Huan ChenNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Wei HanNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yao ChenNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yuan-Yuan ZhangNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Xiao-Hui ZhangNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Lan-Ping XuNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Kai-Yan LiuNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Xiao-Jun HuangNational Clinical Research Center for Treatment of Hematological Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
anti-thymocyte globulincyclophosphamideelderlyfludarabinehaploidentical transplant
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT06946602ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.